An official website of the United States government
Home
Name
Ado-trastuzumab emtansine
Alternate Names
KADCYLA
T-DM 1
TDM 1
Trastuzumab-MCC-DM1 antibody conjugate
Trastuzumab-MCC-DM1 Immunoconjugate
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Antibody-drug conjugate
NSC Number
None
Primary Site
Metastatic HER-2 breast cancer
Histology
None
Remarks
May 3, 2019: FDA approved ado-trastuzumab emtansine (KADCYLA) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
February 22, 2013: Kadcyla received FDA approval for the treatment of metastatic HER-2 positive breast cancer in patients that had previously been treated with trastuzumab and a taxane, either separately or in combination.
February 22, 2013: Kadcyla received FDA approval for the treatment of metastatic HER-2 positive breast cancer in patients that had previously been treated with trastuzumab and a taxane, either separately or in combination.
Coding
This drug should be coded
